Fol­low­ing FDA, CHMP gives thumbs-up on Pfiz­er, BioN­Tech Omi­cron boost­er

One day af­ter the FDA cleared Pfiz­er’s bi­va­lent boost­er to go af­ter Omi­cron, the phar­ma gi­ant and its part­ners at BioN­Tech are now one step clos­er to an EU au­tho­riza­tion.

Pfiz­er and BioN­Tech joint­ly an­nounced Thurs­day that the EMA’s CHMP com­mit­tee rec­om­mend­ed con­di­tion­al mar­ket­ing au­tho­riza­tion for the pair’s Comir­naty bi­va­lent boost­er for Omi­cron to the Eu­ro­pean Com­mis­sion. The bi­va­lent boost­er, which would be ap­proved in peo­ple ages 12 and up, tar­gets both the wild-type SARS-CoV-2 virus and the Omi­cron sub­vari­ant BA.1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER